Surrozen (SRZN) director Shao-Lee Lin exits board without disagreement

Rhea-AI Filing Summary

Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0001824893falseSurrozen, Inc./DENONENONE0001824893srzn:RedeemableWarrantMember2026-01-262026-01-260001824893us-gaap:CommonStockMember2026-01-262026-01-2600018248932026-01-262026-01-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 26, 2026

Surrozen, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39635	30-1374889
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
171 Oyster Point Blvd Suite 400
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 489-9000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SRZN		The Nasdaq Capital Market
Redeemable warrants, each whole warrant exercisable for one-fifteenth of a share of Common Stock		SRZNW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director

On January 26, 2026, Shao-Lee Lin, M.D., Ph.D. resigned from the Board of Directors of Surrozen, Inc., or the Company, effective immediately. Dr. Lin’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Lin for her service and dedication to the Company’s mission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SURROZEN, INC.
Date:	January 30, 2026	By:	/s/ Charles Williams
			Name: Charles Williams Title: Chief Operating Officer

FAQ

What did Surrozen (SRZN) announce in this 8-K filing?

Surrozen announced that director Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors effective January 26, 2026. The company clarified that her departure was not due to any disagreement over Surrozen’s operations, policies, or practices and thanked her for her service.

Why did Shao-Lee Lin resign from Surrozen’s (SRZN) Board of Directors?

Surrozen stated that Dr. Shao-Lee Lin’s resignation from the Board was not because of any disagreement with the company on operations, policies, or practices. The filing does not provide additional reasons, but notes the company’s gratitude for her service and dedication.

When did Surrozen director Shao-Lee Lin’s resignation become effective?

The resignation of Shao-Lee Lin, M.D., Ph.D. from Surrozen’s Board of Directors became effective immediately on January 26, 2026. This effective date is specified in the filing, confirming the timing of her departure from the board role at the company.

Did Surrozen (SRZN) report any disagreement with Dr. Lin related to her resignation?

Surrozen explicitly stated that Dr. Lin’s resignation was not because of any disagreement with the company regarding operations, policies, or practices. This language indicates the departure is characterized as amicable in the disclosure provided to investors and regulators.

Does the Surrozen 8-K mention any replacements for Dr. Shao-Lee Lin on the Board?

The disclosure focuses solely on Dr. Lin’s resignation from Surrozen’s Board of Directors, effective January 26, 2026. It does not identify a successor or replacement director, instead emphasizing there was no disagreement and expressing appreciation for her contributions.

What role did Charles Williams have in Surrozen’s 8-K disclosure?

The 8-K is signed on behalf of Surrozen by Charles Williams, who is identified as the company’s Chief Operating Officer. His signature indicates he is the duly authorized officer executing the report related to Dr. Lin’s board resignation under Exchange Act requirements.